(VIANEWS) – Impinj (PI), Universal Logistics Holdings (ULH), USA Compression Partners, LP (USAC) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Impinj (PI)
27.5% sales growth and 16.08% return on equity
Impinj, Inc. operates a cloud connectivity platform in the Americas, the Asia Pacific, Europe, the Middle East, and Africa. Its platform, which comprises multiple product families, wirelessly connects individual items and delivers data about the connected items to business and consumer applications. The company's platform comprises endpoint ICs, a miniature radios-on-a-chip that attaches to a host item and includes a number to identify the item. Its platform also consists of systems products that comprise reader ICs, readers, and gateways to wirelessly provide power to and communicate bidirectionally with endpoint ICs on host items, as well as to read, write, authenticate, and engage the endpoint ICs on those items; and software and algorithms that enables its partners to deliver use cases, such as retail self-checkout and loss prevention, and warehouse pallet and carton tracking to end-users. The company primarily serves retail, supply chain and logistics, aviation, automotive, healthcare, industrial and manufacturing, sports, food, datacenter, travel, banking, and linen and uniform tracking sectors through distributors, system integrators, value-added resellers, and software solution partners. Impinj, Inc. was incorporated in 2000 and is headquartered in Seattle, Washington.
Earnings Per Share
As for profitability, Impinj has a trailing twelve months EPS of $0.3.
PE Ratio
Impinj has a trailing twelve months price to earnings ratio of 522.43. Meaning, the purchaser of the share is investing $522.43 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.08%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 19.2%, now sitting on 314.98M for the twelve trailing months.
Moving Average
Impinj’s worth is under its 50-day moving average of $160.09 and way above its 200-day moving average of $129.26.
Sales Growth
Impinj’s sales growth is 42.9% for the current quarter and 27.5% for the next.
Volume
Today’s last reported volume for Impinj is 301640 which is 22.4% below its average volume of 388719.
2. Universal Logistics Holdings (ULH)
11.5% sales growth and 23.25% return on equity
Universal Logistics Holdings, Inc. provides transportation and logistics solutions in the United States, Mexico, Canada, and Colombia. It offers truckload services, which include dry van, flatbed, heavy-haul, and refrigerated operations; domestic and international freight forwarding, and customs brokerage services; and final mile and ground expedite services. The company transports various commodities comprising automotive parts, machinery, building materials, paper, food, consumer goods, furniture, steel, and other metals. It also provides value-added services for individual customer requirements, including material handling, consolidation, sequencing, sub-assembly, cross-dock, kitting, repacking, warehousing, and returnable container management; and intermodal support services comprising short-to-medium distance delivery of steamship and rail truck containers between the port or railhead, and the customer and drayage services. Universal Logistics Holdings, Inc. serves automotive, steel, oil and gas, alternative energy, and manufacturing industries, as well as other transportation companies who aggregate loads from various shippers. The company was formerly known as Universal Truckload Services, Inc. and changed its name to Universal Logistics Holdings, Inc. in April 2016. Universal Logistics Holdings, Inc. was founded in 1932 and is headquartered in Warren, Michigan.
Earnings Per Share
As for profitability, Universal Logistics Holdings has a trailing twelve months EPS of $4.85.
PE Ratio
Universal Logistics Holdings has a trailing twelve months price to earnings ratio of 8.16. Meaning, the purchaser of the share is investing $8.16 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.25%.
Volume
Today’s last reported volume for Universal Logistics Holdings is 25662 which is 31.81% below its average volume of 37635.
Yearly Top and Bottom Value
Universal Logistics Holdings’s stock is valued at $39.56 at 06:22 EST, way under its 52-week high of $50.52 and way above its 52-week low of $20.85.
Moving Average
Universal Logistics Holdings’s value is under its 50-day moving average of $40.98 and higher than its 200-day moving average of $36.25.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Aug 30, 2024, the estimated forward annual dividend rate is 0.42 and the estimated forward annual dividend yield is 1.06%.
3. USA Compression Partners, LP (USAC)
8.8% sales growth and 47.01% return on equity
USA Compression Partners, LP provides natural gas compression services in the United States. It offers compression services to oil companies and independent producers, processors, gatherers, and transporters of natural gas and crude oil. The company focuses on providing natural gas compression services to infrastructure applications, including centralized natural gas gathering systems and processing facilities, as well as gas lift applications for crude oil wells. As of December 31, 2023, it had 3,775,660 horsepower in its fleet. USA Compression Partners, LP was founded in 1998 and is headquartered in Austin, Texas.
Earnings Per Share
As for profitability, USA Compression Partners, LP has a trailing twelve months EPS of $0.52.
PE Ratio
USA Compression Partners, LP has a trailing twelve months price to earnings ratio of 43.29. Meaning, the purchaser of the share is investing $43.29 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 47.01%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Jul 22, 2024, the estimated forward annual dividend rate is 2.1 and the estimated forward annual dividend yield is 9.33%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 13.7%, now sitting on 906.72M for the twelve trailing months.
4. Jazz Pharmaceuticals plc (JAZZ)
6.2% sales growth and 10.84% return on equity
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors. Its lead marketed products in neuroscience include Xywav, an oral solution for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy and idiopathic hypersomnia (IH); Xyrem, a sodium oxybate oral solution for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older; and Epidiolex, a cannabidiol oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients one year of age or older. The company's lead marketed products in oncology comprise Zepzelca for the treatment of adult patients with metastatic small cell lung cancer; Rylaze, a product for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adults and pediatric patients aged one month or older who has developed hypersensitivity to E. coli-derived asparaginase; Vyxeos, a liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation. It has licensing and collaboration agreements with Zymeworks Inc.; Sumitomo Pharma Co., Ltd; Werewolf Therapeutics, Inc.; Codiak BioSciences, Inc.; Ligand Pharmaceuticals Incorporated; XL-protein GmbH; and Redx Pharma plc. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.
Earnings Per Share
As for profitability, Jazz Pharmaceuticals plc has a trailing twelve months EPS of $5.9.
PE Ratio
Jazz Pharmaceuticals plc has a trailing twelve months price to earnings ratio of 19.11. Meaning, the purchaser of the share is investing $19.11 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.84%.
Volume
Today’s last reported volume for Jazz Pharmaceuticals plc is 475027 which is 31.77% below its average volume of 696282.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 14% and 20.7%, respectively.
Sales Growth
Jazz Pharmaceuticals plc’s sales growth for the next quarter is 6.2%.
5. Veeco Instruments (VECO)
5.2% sales growth and 12.51% return on equity
Veeco Instruments Inc., together with its subsidiaries, develops, manufactures, sells, and supports semiconductor and thin film process equipment primarily to make electronic devices worldwide. The company offers laser annealing, ion beam deposition and etch, metal organic chemical vapor deposition, single wafer wet processing and surface preparation, molecular beam epitaxy, and atomic layer deposition and other deposition systems, as well as packaging lithography equipment. Its process equipment systems are used in the production of a range of microelectronic components, including logic, dynamic random-access memory, photonics devices, power electronics, radio frequency filters and amplifiers, thin film magnetic heads, and other semiconductor devices. The company markets and sells its products to integrated device manufacturers and foundries; outsourced semiconductor assembly and test, hard disk drive, and photonics manufacturers; and research centers and universities. Veeco Instruments Inc. was founded in 1945 and is headquartered in Plainview, New York.
Earnings Per Share
As for profitability, Veeco Instruments has a trailing twelve months EPS of $1.53.
PE Ratio
Veeco Instruments has a trailing twelve months price to earnings ratio of 20.65. Meaning, the purchaser of the share is investing $20.65 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.51%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 8.8%, now sitting on 701.65M for the twelve trailing months.
